AGNPF
Algernon Health Inc.
Price Chart
Latest Quote
$0.04
Current Price| Previous Close | $0.04 |
| Open | $0.03 |
| Day High | $0.04 |
| Day Low | $0.03 |
| Volume | 3,112 |
Stock Information
Note: Financial values converted from CAD to USD
| Shares Outstanding | 47.33M |
| Cash Equivalents | $154K |
| Net Income | $-1.41M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.71M |
| EPS (TTM) | $-0.04 |
| Exchange | OQB |
đ Custom Metrics & Score
Score: 6/42| Debt to Equity | 0.81 |
| Debt to Earnings | -1.27 |
| Current Ratio | 0.25 |
| Quick Ratio | 0.09 |
| Return on Equity | -63.71% |
| Avg FCF Growth | -15.33% |
| FCF Yield | -68.94% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $0.04 | 3,000 |
| 2026-01-30 | $0.04 | 4,764 |
| 2026-01-29 | $0.04 | 2,352 |
| 2026-01-28 | $0.04 | 15,000 |
| 2026-01-27 | $0.04 | 0 |
| 2026-01-26 | $0.04 | 1,616 |
| 2026-01-23 | $0.03 | 1,250 |
| 2026-01-22 | $0.04 | 12,813 |
| 2026-01-21 | $0.04 | 0 |
| 2026-01-20 | $0.04 | 22,560 |
| 2026-01-16 | $0.04 | 2,136 |
| 2026-01-15 | $0.04 | 0 |
| 2026-01-14 | $0.04 | 22,476 |
| 2026-01-13 | $0.05 | 1,552 |
| 2026-01-12 | $0.04 | 3,230 |
| 2026-01-09 | $0.04 | 1,259 |
| 2026-01-08 | $0.04 | 1,400 |
| 2026-01-07 | $0.04 | 0 |
| 2026-01-06 | $0.04 | 2,652 |
| 2026-01-05 | $0.04 | 6,000 |
About Algernon Health Inc.
Algernon Health Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. Its pipeline includes repirinast for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine for the treatment of strokes and traumatic brain injuries. The company was formerly known as Algernon Pharmaceuticals Inc. and changed its name to Algernon Health Inc. in October 2025. Algernon Health Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Income Statement (Annual)
Revenue
| Metric | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
Expenses
| Metric | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|
| Total Expenses | $1,717,794 | $2,412,042 | $5,241,991 | $6,019,955 |
| Net Non Operating Interest Income Expense | $739 | $1,368 | $2,097 | $2,078 |
| Operating Expense | $1,717,794 | $2,412,042 | $5,241,991 | $6,019,955 |
| Selling And Marketing Expense | $423,003 | $321,352 | $1,260,704 | $729,798 |
| General And Administrative Expense | $1,214,225 | $1,439,533 | $2,886,128 | $2,996,709 |
| Other Income Expense | - | $1,907,692 | $-1,541,306 | $-36,479 |
| Other Non Operating Income Expenses | - | $1,662,231 | - | - |
| Other Operating Expenses | - | - | $210,134 | $231,755 |
Income & Earnings
| Metric | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-1,717,055 | $-502,982 | $-6,781,200 | $-6,054,356 |
| Net Interest Income | $739 | $1,368 | $2,097 | $2,078 |
| Interest Income | $739 | $1,368 | $2,097 | $2,078 |
| Normalized Income | $-1,717,055 | $-748,443 | $-5,239,894 | $-6,017,877 |
| Net Income From Continuing And Discontinued Operation | $-1,717,055 | $-502,982 | $-6,781,200 | $-6,054,356 |
| Net Income Common Stockholders | $-1,717,055 | $-502,982 | $-6,781,200 | $-6,054,356 |
| Net Income | $-1,717,055 | $-502,982 | $-6,781,200 | $-6,054,356 |
| Net Income Including Noncontrolling Interests | $-1,717,055 | $-502,982 | $-6,781,200 | $-6,054,356 |
| Net Income Continuous Operations | $-1,717,055 | $-502,982 | $-6,781,200 | $-6,054,356 |
| Pretax Income | $-1,717,055 | $-502,982 | $-6,781,200 | $-6,054,356 |
| Special Income Charges | $0 | $245,461 | $-1,541,306 | $-36,479 |
| Interest Income Non Operating | $739 | $1,368 | $2,097 | $2,078 |
| Operating Income | $-1,717,794 | $-2,412,042 | $-5,241,991 | $-6,019,955 |
Per Share Metrics
| Metric | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|
| Diluted EPS | - | $-0.03 | $-0.45 | $-0.87 |
| Basic EPS | - | $-0.03 | $-0.45 | $-0.87 |
Other
| Metric | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-1,663,102 | $-2,630,941 | $-3,650,287 | $-5,948,540 |
| Total Unusual Items | $0 | $245,461 | $-1,541,306 | $-36,479 |
| Total Unusual Items Excluding Goodwill | $0 | $245,461 | $-1,541,306 | $-36,479 |
| Reconciled Depreciation | $54,692 | $26,562 | $50,398 | $34,936 |
| EBITDA (Bullshit earnings) | $-1,663,102 | $-2,385,480 | $-5,191,593 | $-5,985,019 |
| EBIT | $-1,717,794 | $-2,412,042 | $-5,241,991 | $-6,019,955 |
| Diluted NI Availto Com Stockholders | $-1,717,055 | $-502,982 | $-6,781,200 | $-6,054,356 |
| Research And Development | $80,566 | $651,157 | $1,095,159 | $2,293,448 |
| Selling General And Administration | $1,637,228 | $1,760,885 | $4,146,832 | $3,726,507 |
| Other Gand A | $449,488 | $347,854 | $941,185 | $1,400,135 |
| Salaries And Wages | $764,737 | $1,091,679 | $1,944,943 | $1,596,574 |
| Diluted Average Shares | - | $20,047,990 | $15,147,365 | $6,952,539 |
| Basic Average Shares | - | $20,047,990 | $15,147,365 | $6,952,539 |
| Other Special Charges | - | $-245,461 | - | - |
| Impairment Of Capital Assets | - | $0 | $1,541,306 | $36,479 |
Balance Sheet (Annual)
Assets
| Metric | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|
| Net Tangible Assets | $-1,599,018 | $-1,007,934 | $-2,322,431 | $368,499 |
| Fixed Assets Revaluation Reserve | $589,500 | $0 | - | - |
| Total Assets | $4,877,474 | $3,944,040 | $4,193,699 | $8,140,757 |
| Total Non Current Assets | $4,323,002 | $3,205,277 | $3,853,870 | $5,313,659 |
| Other Non Current Assets | $28,750 | $28,750 | $57,500 | $57,500 |
| Goodwill And Other Intangible Assets | $4,294,252 | $3,176,527 | $3,796,370 | $5,256,159 |
| Other Intangible Assets | $4,294,252 | $3,176,527 | $3,796,370 | $5,256,159 |
| Current Assets | $554,472 | $738,763 | $339,829 | $2,827,098 |
| Prepaid Assets | $360,933 | $126,879 | $118,688 | $753,060 |
| Receivables | $17,038 | $15,686 | $96,056 | $665,529 |
| Taxes Receivable | $16,593 | $15,242 | $95,041 | $665,048 |
| Accrued Interest Receivable | $445 | $444 | $1,015 | $481 |
| Cash Cash Equivalents And Short Term Investments | $176,501 | $596,198 | $125,085 | $1,408,509 |
| Cash And Cash Equivalents | $176,501 | $596,198 | $125,085 | $1,408,509 |
Liabilities
| Metric | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $2,182,240 | $1,775,447 | $2,719,760 | $2,516,099 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $2,182,240 | $1,775,447 | $2,719,760 | $2,516,099 |
| Payables And Accrued Expenses | $2,182,240 | $1,775,447 | $2,719,760 | $2,516,099 |
Equity
| Metric | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|
| Common Stock Equity | $2,695,234 | $2,168,593 | $1,473,939 | $5,624,658 |
| Total Equity Gross Minority Interest | $2,695,234 | $2,168,593 | $1,473,939 | $5,624,658 |
| Stockholders Equity | $2,695,234 | $2,168,593 | $1,473,939 | $5,624,658 |
| Other Equity Interest | $737,100 | - | - | - |
| Gains Losses Not Affecting Retained Earnings | $2,354,970 | $3,369,289 | $4,116,349 | $3,696,162 |
| Other Equity Adjustments | $1,765,470 | $3,369,289 | $4,116,349 | $3,696,162 |
| Retained Earnings | $-30,564,596 | $-30,755,831 | $-30,792,342 | $-25,186,887 |
Other
| Metric | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $34,256,219 | $27,300,819 | $15,775,757 | $11,256,999 |
| Share Issued | $34,256,219 | $27,300,819 | $15,775,757 | $11,256,999 |
| Tangible Book Value | $-1,599,018 | $-1,007,934 | $-2,322,431 | $368,499 |
| Invested Capital | $2,695,234 | $2,168,593 | $1,473,939 | $5,624,658 |
| Working Capital | $-1,627,768 | $-1,036,684 | $-2,379,931 | $310,999 |
| Total Capitalization | $2,695,234 | $2,168,593 | $1,473,939 | $5,624,658 |
| Capital Stock | $30,167,760 | $29,555,135 | $28,149,932 | $27,115,383 |
| Common Stock | $30,167,760 | $29,555,135 | $28,149,932 | $27,115,383 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|
| Free Cash Flow | $-1,182,007 | $-2,793,602 | $-2,612,508 | $-3,057,349 |
Operating Activities
| Metric | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-1,157,041 | $-2,709,577 | $-2,553,008 | $-2,912,741 |
| Cash Flow From Continuing Operating Activities | $-1,157,041 | $-2,709,577 | $-2,553,008 | $-2,912,741 |
| Operating Gains Losses | $52,070 | $-1,658,158 | $73,950 | $-45,121 |
Investing Activities
| Metric | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|
| Capital Expenditure | $-24,966 | $-84,025 | $-59,500 | $-144,608 |
| Investing Cash Flow | $150,034 | $2,279,948 | $-59,500 | $-144,608 |
| Cash Flow From Continuing Investing Activities | $150,034 | $2,279,948 | $-59,500 | $-144,608 |
| Net Other Investing Changes | $175,000 | $-350,427 | - | - |
Financing Activities
| Metric | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $587,100 | $893,589 | $1,225,980 | $2,055,123 |
| Financing Cash Flow | $587,308 | $901,089 | $1,328,909 | $2,055,123 |
| Cash Flow From Continuing Financing Activities | $587,308 | $901,089 | $1,328,909 | $2,055,123 |
| Net Common Stock Issuance | $587,100 | $893,589 | $1,225,980 | $2,055,123 |
| Common Stock Issuance | $587,100 | $893,589 | $1,225,980 | $2,055,123 |
| Net Other Financing Charges | - | - | - | - |
Other
| Metric | 2025-08-31 | 2024-08-31 | 2023-08-31 | 2022-08-31 |
|---|---|---|---|---|
| Interest Paid Supplemental Data | $0 | $0 | $0 | $0 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $176,501 | $596,198 | $125,085 | $1,408,509 |
| Beginning Cash Position | $596,198 | $125,085 | $1,408,509 | $2,411,163 |
| Effect Of Exchange Rate Changes | $2 | $-347 | $175 | $-428 |
| Changes In Cash | $-419,699 | $471,460 | $-1,283,599 | $-1,002,226 |
| Proceeds From Stock Option Exercised | $208 | $7,500 | $102,929 | $0 |
| Net Intangibles Purchase And Sale | $-24,966 | $2,630,375 | $-59,500 | $-144,608 |
| Sale Of Intangibles | $0 | $2,714,400 | $0 | - |
| Purchase Of Intangibles | $-24,966 | $-84,025 | $-59,500 | $-144,608 |
| Change In Working Capital | $257,131 | $-616,196 | $1,265,717 | $2,584,486 |
| Change In Payables And Accrued Expense | $423,229 | $-688,480 | $63,543 | $1,519,839 |
| Change In Prepaid Assets | $-164,704 | $-8,191 | $634,372 | $-549,844 |
| Change In Receivables | $-1,394 | $80,475 | $567,802 | $1,614,491 |
| Changes In Account Receivables | $-1,394 | $80,475 | $567,802 | $1,614,491 |
| Stock Based Compensation | $196,121 | $286,658 | $1,256,821 | $530,835 |
| Depreciation Amortization Depletion | $54,692 | $26,562 | $50,398 | $34,936 |
| Depreciation And Amortization | $54,692 | $26,562 | $50,398 | $34,936 |
| Amortization Cash Flow | $54,692 | $26,562 | $50,398 | $34,936 |
| Amortization Of Intangibles | $54,692 | $26,562 | $50,398 | $34,936 |
| Net Foreign Currency Exchange Gain Loss | $52,070 | $4,073 | $73,950 | $-45,121 |
| Gain Loss On Sale Of PPE | $0 | $-1,662,231 | $0 | - |
| Net Income From Continuing Operations | $-1,717,055 | $-502,982 | $-6,781,200 | $-6,054,356 |
| Other Non Cash Items | - | $-245,461 | $40,000 | - |
| Asset Impairment Charge | - | $0 | $1,541,306 | $36,479 |